Diabetes Mellitus News and Research

RSS
Diabetes mellitus is a severe and debilitating chronic disease that develops in nearly 5 percent of the world’s population. People with this disease have a shortage of insulin or a reduced ability to use insulin, the hormone regulating blood glucose levels, which is normally produced by the pancreas. In the United States alone, an estimated 18 million people have diabetes, and each year about 1 million Americans are diagnosed with the disease. It is the sixth leading cause of death in the US and is responsible for over 200,000 deaths a year. Insulin-dependent (type I) diabetes accounts for around 10% of diabetics. For those patients, suffering from an inability of their pancreas to produce insulin, the only practical treatment possible is regular insulin replacement by multiple daily injections. Transplantation of a pancreas or pancreatic tissue would be beneficial to millions of such patients in that it would restore their normal ability to produce self insulin. Transplantation of human pancreas or pancreatic islets is a practiced and time-honored such therapeutic approach, but is extremely limited by the severe shortage of human donor organs. Tissera's R&D efforts in this domain are directed towards the development of a universally available and reliable source of animal fetal donor pancreatic precursor tissue, suitable for transplantation and eventual normal structural and functional growth in human diabetics.
Safety profiles of JANUVIA and JANUMET drugs established through clinical development program

Safety profiles of JANUVIA and JANUMET drugs established through clinical development program

European CHMP recommends Merck's JANUVIA and JANUMET as add-on to insulin

European CHMP recommends Merck's JANUVIA and JANUMET as add-on to insulin

Stem Cell Therapy International merges with Histostem

Stem Cell Therapy International merges with Histostem

Diabetes prevalence highest in the Southern and Appalachian states

Diabetes prevalence highest in the Southern and Appalachian states

Study reveals that AIR Inhaled Insulin is inferior to SC insulin

Study reveals that AIR Inhaled Insulin is inferior to SC insulin

Drug-eluting stents effective for diabetic patients

Drug-eluting stents effective for diabetic patients

Results from the BLOSSOM trial announced by Arena Pharmaceuticals

Results from the BLOSSOM trial announced by Arena Pharmaceuticals

Study reveals ineffectiveness of insulin and metformin against inflammatory biomarkers

Study reveals ineffectiveness of insulin and metformin against inflammatory biomarkers

Lexicon initiates Phase 2 clinical trial of LX4211 in patients with type 2 diabetes mellitus

Lexicon initiates Phase 2 clinical trial of LX4211 in patients with type 2 diabetes mellitus

Clinical trial data of Genous Bio-engineered R stent to be presented

Clinical trial data of Genous Bio-engineered R stent to be presented

Final results of SAPHRIS clinical study released

Final results of SAPHRIS clinical study released

Laquinimod study data reveals its neuroprotective and anti-inflammatory properties

Laquinimod study data reveals its neuroprotective and anti-inflammatory properties

Abbreviated New Drug Application for nateglinide tablets approved

Abbreviated New Drug Application for nateglinide tablets approved

Phase II human clinical trial of Exsulin commences

Phase II human clinical trial of Exsulin commences

New findings may help identify treatments for diabetes and hyperinsulinemia

New findings may help identify treatments for diabetes and hyperinsulinemia

Teva Pharmaceutical Industries to present MS treatment research data

Teva Pharmaceutical Industries to present MS treatment research data

Takeda receives FDA response regarding NDA for fixed-dose combination of alogliptin and ACTOS

Takeda receives FDA response regarding NDA for fixed-dose combination of alogliptin and ACTOS

Researchers demystify polar body analysis reproduction technique

Researchers demystify polar body analysis reproduction technique

RE-LY trial establishes effectiveness of PRADAX in reducing stroke risk in AF patients

RE-LY trial establishes effectiveness of PRADAX in reducing stroke risk in AF patients

Oral dabigatran etexilate reduces the risk of stroke and systemic embolism

Oral dabigatran etexilate reduces the risk of stroke and systemic embolism

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.